GreenLight Biosciences, Inc.
200 Boston Avenue
About GreenLight Biosciences, Inc.
GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible.
GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection and support the health of bees and other pollinators. The GreenLight team values diversity, inclusion, and equality and promises to use collaboration to remain scientifically imaginative and passionately focused on making a difference in the world.
44 articles with GreenLight Biosciences, Inc.
GreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
GreenLight Biosciences Holdings, PBC today reported operational highlights and financial results for the third quarter ended September 30, 2022.
GreenLight Biosciences announced that Dr. Andrey Zarur, CEO, and Susan Keefe, CFO will participate in two upcoming investor conferences in November.
As part of a realignment, GreenLight Biosciences is cutting staff by about 25%, the company announced Wednesday.
GreenLight Biosciences announced a realignment to focus on key near-term value drivers and extend its cash runway.
GreenLight Biosciences and Queensland University of Technology partner to tackle destructive fall armyworm using RNA
GreenLight Biosciences and Queensland University of Technology (QUT) partner to create a solution for fall armyworm.
GreenLight Biosciences Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
GreenLight Biosciences today reported operational highlights and financial results for the second quarter ended June 30, 2022.
CRISPR Therapeutics, Clovis Oncology and VistaGen all released Q2 results this week, while GreenLight Biosciences has some extra cash to work with.
GreenLight Biosciences today announced a private placement of approximately $109 million.
GreenLight Biosciences and Samsung Biologics complete first commercial-scale engineering run for mRNA Covid-19 vaccine
GreenLight Biosciences and Samsung Biologics announced the successful completion of the first commercial-scale engineering run for the companies’ mRNA production partnership.
GreenLight Biosciences has announced a collaboration with the National Institutes of Health to develop COVID-19 vaccines that are more broadly protective against new variants and with longer-lasting effects.
An RNA-based solution by GreenLight Biosciences designed to protect honeybees from the Varroa destructor mite was named a finalist by Fast Company for its 2022 World Changing Ideas Awards.
GreenLight Biosciences, PBC, a biotechnology company focused on RNA research, product design, development, and manufacturing for human, animal, and plant health, is proud to welcome Barney Graham, MD, PhD., to its Human Health Scientific Advisory Board.
GreenLight Biosciences Holdings, PBC (GRNA) enters into multitarget licensing agreement with Serum Institute of India to develop and commercialize messenger RNA products for emerging markets globally
GreenLight Biosciences Holdings PBC today announced a licensing agreement with Serum Institute of India, Pvt, Ltd., aimed at accelerating accessibility to messenger RNA products in emerging markets globally.
GreenLight Biosciences begins trading today as Nasdaq: GRNA on the closing of its business combination with Environmental Impact Acquisition Corp.
GreenLight Biosciences ("GreenLight"), a biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible for human health and agriculture, and Environmental Impact Acquisition Corp. (Nasdaq: ENVI) ("ENVI"), a special purpose acquisition company, yesterday announced the closing of their previously announced business combination.
ENVI and GreenLight Biosciences Announce Filing of Definitive Proxy Statement/Prospectus and the February 1st, 2022 Special Meeting to Approve Proposed Business Combination
Environmental Impact Acquisition Corporation announced today that ENVI's definitive proxy statement/prospectus (the "Proxy Statement") relating to the previously announced business combination with GreenLight Biosciences, Inc.
GreenLight Biosciences and IAVI, a nonprofit scientific research organization, announced work on a messenger RNA vaccine candidate to tackle the COVID-19 Omicron variant.
GreenLight Biosciences and Samsung Biologics announce collaboration to build capacity for messenger RNA Vaccine Manufacturing
GreenLight Biosciences and Samsung Biologics announced a partnership agreement in which Samsung Biologics will manufacture GreenLight's messenger RNA COVID-19 vaccine candidate at commercial scale.
Serum Life Sciences invests in RNA biotech GreenLight by joining expanded financing for Environmental Impact Acquisition Corp.
GreenLight Biosciences Inc., an RNA-focused biotech, and Environmental Impact Acquisition Corp. announced an expansion of its PIPE financing to an aggregate $124 million in gross proceeds.
Many mergers took place in 2021. Here’s a look at some of the hottest life sciences SPAC merger announcements so far in 2021. Many mergers took place in 2021,
GreenLight Biosciences is delighted to announce the appointment of Professor Diane E. Griffin, MD, PhD, and Emmanuel Hanon, DVM, PhD, to its Human Health Scientific Advisory Board.